case 1: impact of the bcg shortage in bladder cancer
Published 4 years ago • 120 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
3:08
case 1: non-muscle invasive, bcg-refractory bladder cancer
-
3:20
case 1: treatments for nmibc refractory to bcg
-
8:35
case 1: novel agents in superficial bladder cancer
-
2:55
bladder: bcg shortage
-
15:48
managing nmibc in the bcg shortage era
-
7:41
bcg-refractory superficial bladder cancer
-
2:49
management of bcg failure in non-muscle invasive bladder cancer - medpage today
-
2:38
impact of re-tur on bcg-treated t1 hg/g3 bladder cancer
-
3:47
bcg shortage and changing treatment patterns for non-muscle-invasive bladder cancer
-
50:41
management of bcg-unresponsive non-muscle invasive bladder cancer
-
15:03
t1 bladder cancer
-
5:24
case 3: fgfr-targeted therapy adverse events in bladder cancer
-
1:01:32
urowebinar: practical management of bladder cancer
-
43:50
urowebinar: new treatments development in nmibc
-
1:47
current and upcoming clinical trials in bladder cancer
-
14:50
bcg unresponsive disease
-
1:27:50
evolving role of bcg in non-muscle invasive bladder cancer-myths & facts
-
1:08:14
urowebinar: bcg unresponsive disease how this definition impact your treatment decision making
-
26:18
controversies in non-muscle invasive bladder cancer (nmibc): guidelines and beyond 2023